In the Phase 3 INO-VATE trial (NCT01564784), adult patients (age range 18–78 years) with R/R CD22+ BCP-ALL were randomised to either receive inotuzumab ozogamicin or standard-of-care chemotherapy (23). Here, OPN1SW is linked to acute lymphoblastic leukemia.